Akebia Therapeutics (AKBA) Revenue (2017 - 2026)

Akebia Therapeutics (AKBA) has 10 years of Revenue data on file, last reported at $53.5 million in Q1 2026.

• Revenue for Q1 2026 came in at $53.5 million, down 6.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $232.4 million (up 25.69% YoY), and the FY2025 annual result was $236.2 million, up 47.46% from the prior year.
• Revenue slipped to $53.5 million in Q1 2026 per AKBA's latest filing, from $57.6 million in the prior quarter.
• Over five years, Revenue peaked at $62.5 million in Q2 2025 and troughed at $32.6 million in Q1 2024.
• A 5-year average of $49.0 million and a median of $48.7 million in 2022 frame the typical range for Revenue.
• The sharpest annual moves came in 2022 and 2024: Revenue jumped 136.68% in 2022, then slipped 22.58% in 2024.
• A 5-year view of Revenue shows it stood at $55.8 million in 2022, then gained by 0.74% to $56.2 million in 2023, then declined by 17.26% to $46.5 million in 2024, then grew by 23.93% to $57.6 million in 2025, then dropped by 7.08% to $53.5 million in 2026.
• Business Quant data shows AKBA's Revenue at $53.5 million in Q1 2026, $57.6 million in Q4 2025, and $58.8 million in Q3 2025.